Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AML patients in first relapse or refractory after all prior therapy~* Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2~Exclusion Criteria:~* Diagnosis of acute promyelocytic leukemia~* AML secondary to prior chemotherapy for other neoplasms.~* Persistent, clinically significant \> Grade 1 non-hematologic toxicity from prior AML therapy~* Prior treatment with a FLT3 targeted therapy~* Active infection not well controlled by antibacterial, antifungal and/or antiviral therapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Initial dose 30 mg/day quizartinib (Type: EXPERIMENTAL): Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
- Initial dose 20 mg/day quizartinib (Type: EXPERIMENTAL): Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).